Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Ibsa Institut Biochimique SA

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Ibsa Institut Biochimique SA

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Ibsa Institut Biochimique SA. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 24, 2026 to Jul 24, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MOZ appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P110005, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Via Al Ponte 13, Ch-6903, Lugano Ticino, 6903. Recorded on P110005/S015, decision dated Jul 24, 2026.

Changes described in PMA records

P110005/S015: Gelsyn-3

FDA’s recorded scope: Approved for the addition of a new dispensing area, Room A107, for the sampling and weighing of raw materials used in the manufacture of GELSYN-3 (sodium hyaluronate 0.84%) at the IBSA Farmaceutici Italia Srl facility in San Grato-Lodi, Italy, under the same FEI as the currently approved dispensing area

Jul 24, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Gelsyn-3P110005/S015
Ibsa Institut Biochimique SAPMA supplementJul 24, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.